Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0373 | 1 | 1 |
Mycobacterium ulcerans | hypothetical protein | 0.022 | 0.2852 | 0.5 |
Entamoeba histolytica | phosphoglycerate mutase family protein, putative | 0.022 | 0.2852 | 0.5 |
Echinococcus multilocularis | 6 phosphofructo 2 kinase:fructose 2 | 0.0373 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0367 | 0.9706 | 0.9604 |
Trypanosoma brucei | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0373 | 1 | 1 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0367 | 0.9706 | 0.9706 |
Trypanosoma brucei | 6-phosphofructo-2-kinase 2 | 0.0367 | 0.9706 | 0.9706 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0373 | 1 | 1 |
Onchocerca volvulus | 0.0373 | 1 | 0.5 | |
Loa Loa (eye worm) | hypothetical protein | 0.0373 | 1 | 1 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.0367 | 0.9706 | 0.9706 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0373 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.022 | 0.2852 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.0367 | 0.9706 | 0.9706 |
Schistosoma mansoni | 6-phosphofructokinase | 0.0373 | 1 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.022 | 0.2852 | 0.5 |
Mycobacterium ulcerans | fructose-2,6-bisphosphatase GpmB | 0.022 | 0.2852 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | = 34 % | Cytotoxicity against bortezomib-resistant human THP1 cells assessed as cell viability at 10 uM after 72 hrs by MTS assay relative to vehicle-treated control | ChEMBL. | 23789888 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.